We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+37.96%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$239M
Cap. Flow
+$117M
Cap. Flow %
10.4%
Top 10 Hldgs %
67.61%
Holding
75
New
17
Increased
14
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$58.1M
2
YMAB
Y-mAbs Therapeutics
YMAB
+$53.5M
3
SNY icon
Sanofi
SNY
+$17.6M
4
PBYI icon
Puma Biotechnology
PBYI
+$13.3M
5
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$12.4M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$14.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$9.46M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$8.96M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.8M
5
BLUE
bluebird bio
BLUE
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 85.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
51
DELISTED
Esperion Therapeutics
ESPR
$1.62M 0.14%
36,599
-114,562
-76% -$5.26M
SNDX icon
52
Syndax Pharmaceuticals
SNDX
$1.84B
$1.4M 0.12%
173,112
+74,499
+76% +$531K
KDNY
53
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.39M 0.12%
37,916
-10,348
-21% -$332K
ADAP
54
DELISTED
Adaptimmune Therapeutics
ADAP
$1.22M 0.11%
+89,919
New +$943K
OCGN icon
55
Ocugen
OCGN
$410M
$1.13M 0.1%
34,617
– –
KALA icon
56
KALA BIO
KALA
$11.8M
$944K 0.08%
38
-83
-69% -$2.53M
OMED
57
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$839K 0.07%
395,744
-500
-0.1% -$1.2K
BLUE
58
DELISTED
bluebird bio
BLUE
– –
-4,275
Closed -$8.69M
CRSP icon
59
PUT
CRISPR Therapeutics
CRSP
$4.58B
– –
-200,000
Closed -$11.8M
PTCT icon
60
PTC Therapeutics
PTCT
$6.37B
– –
-127,079
Closed -$4.29M
ICPT
61
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-106,817
Closed -$8.96M
CYTO
62
DELISTED
Altamira Therapeutics Ltd
CYTO
$0 ﹤0.01%
18
– –
RETA
63
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-89,909
Closed -$3.14M
SPPI
64
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-169,965
Closed -$3.56M
CCXI
65
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-68,258
Closed -$899K
CALA
66
DELISTED
Calithera Biosciences, Inc
CALA
– –
-14,861
Closed -$1.49M
GWPH
67
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-63,070
Closed -$8.8M
AMAG
68
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-142,511
Closed -$2.78M
FTSV
69
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-23,700
Closed -$379K
CELG
70
DELISTED
Celgene Corp
CELG
– –
-184,399
Closed -$14.6M
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Sofinnova Investments held 75 positions worth $1.12B, up 27% from $883M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments deployed $117M of net new capital in Q3 2018, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Principia Biopharma Inc. Common Stock: 2,059,146 shares worth $59.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $9.46M trimmed.

  • Sofinnova Investments's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,059,146 shares worth $59.6M.
  • Sofinnova Investments added most to Puma Biotechnology in Q3 2018, an estimated $13.3M increase.
  • Sofinnova Investments's biggest Q3 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $9.46M.
  • Sofinnova Investments fully exited Celgene Corp in Q3 2018, selling an estimated $14.6M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.12B portfolio in Q3 2018.
  • Sofinnova Investments opened 17 new positions and closed 14 in Q3 2018.
  • Sofinnova Investments's portfolio value rose 27% quarter-over-quarter to $1.12B.

Based on Sofinnova Investments's 13F filing for Q3 2018, filed 15 Nov 2018.